Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 13,820 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $105,308.40. Following the completion of the transaction, the chief financial officer directly owned 250,996 shares in the company, valued at approximately $1,912,589.52. This trade represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The stock was sold at an average price of $8.45, for a total transaction of $14,322.75.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY traded up $0.06 during mid-day trading on Thursday, hitting $7.71. The company had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. Relay Therapeutics, Inc. has a one year low of $1.77 and a one year high of $9.04. The firm has a fifty day moving average price of $7.93 and a 200 day moving average price of $5.93. The company has a market capitalization of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Research analysts expect that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Commodore Capital LP purchased a new position in shares of Relay Therapeutics in the 2nd quarter worth about $46,191,000. TCG Crossover Management LLC bought a new stake in Relay Therapeutics in the third quarter worth about $9,450,000. Woodline Partners LP raised its position in Relay Therapeutics by 448.4% in the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after acquiring an additional 1,241,657 shares during the period. Bellevue Group AG boosted its stake in Relay Therapeutics by 11.6% in the second quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock valued at $28,479,000 after acquiring an additional 853,578 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Relay Therapeutics during the 2nd quarter valued at approximately $2,892,000. Institutional investors own 96.98% of the company’s stock.

Wall Street Analysts Forecast Growth

RLAY has been the topic of a number of research reports. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $13.00 in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Finally, Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Relay Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.